On August 29, 2025, British American Tobacco (BAT) released the latest episode of their podcast "The Smokeless World" on YouTube. 2Firsts summarized the content of the show.
BAT’s Director of Science and Research, James Murphy, stated that the company is currently at a crucial stage of transitioning from combustion cigarettes to smokeless products, and they anticipate gradually ceasing cigarette sales in some markets in the future.
Murphy pointed out that BAT had invested heavily in research and development of "safer cigarettes" in the 2000s, but clinical trials showed that disease-related biomarkers did not improve. This ultimately forced the company to shift its focus to the development of smoke-free products. Today, BAT's sales of smoke-free products in Japan and the UK have exceeded those of cigarettes, with this ratio being over 70% in Sweden.
He highlighted the experience of Swedish Snus: the local adult smoking rate is only 5.4%, the lowest in the world, close to the World Health Organization's "smoke-free society" standard of 5%. At the same time, smoking-related diseases in Sweden are at their lowest levels in the European Union. Murphy said that if the EU as a whole adopts a similar model, it could potentially save 3.5 million lives in the next decade.
In the field of scientific communication, BAT has launched OMNI™, a database compiling 170,000 words and featuring research findings from over 300 scientists. The reference volume from this dataset is twice that of internal research at the company, positioning it as an "evidence platform for harm reduction in tobacco." It has already been launched in 15 markets including Japan and Germany.
Murphy stated that the company's goal is to normalize harm reduction in tobacco, but the path to achieving this will vary depending on the market. He bluntly said, "There will be a future market where BAT no longer sells cigarettes, but this will be a gradual process.
Caption: James Murphy (right) is in conversation with the host | Image source: BAT
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
